Abstract

CLINICAL TRIALS SUPPORT CORE The Clinical Trials Support Core (CTSC) is a shared resource available to all members of the UICC. It is designed to facilitate execution of high quality clinical cancer investigation. The CTSC enhances interaction among UICC members and provides for easy assembly of multi- departmental teams needed for collaboration on innovative protocols. The CTSC is composed of dedicated staff with expertise in protocol management and study coordination. Administratively, the Director of the CTSC reports to the Associate Director for Clinical Research. The CTSC provides investigators with appropriate routing of protocols through the various internal regulatory committees including the UICC Protocol Review Committee, assists the investigator in protocol modifications and reporting adverse events for ongoing clinical studies, and supplies staff with expertise in data management. The CTSC also participates in posting protocol lists and supporting internal communication about ongoing studies, as well as statistical reporting on accrual. A chargeback system is used to compensate the CTSC of most clinical trials run through the CTSC, however the core also supports innovative, early phase clinical trials for which there is no other source of support.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-02
Application #
6470079
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2001-07-01
Project End
2002-06-30
Budget Start
Budget End
Support Year
2
Fiscal Year
2001
Total Cost
Indirect Cost

  Institution

Name
University of Iowa
Department
Type
DUNS #
041294109
City
Iowa City
State
IA
Country
United States
Zip Code
52242

  Publications

Xiu, Yan; Dong, Qianze; Li, Qingchang et al. (2018) Stabilization of NF-?B-Inducing Kinase Suppresses MLL-AF9-Induced Acute Myeloid Leukemia. Cell Rep 22:350-358
Armer, Jessica S; Clevenger, Lauren; Davis, Lauren Z et al. (2018) Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. Cancer 124:3401-3408
Mayo, Zachary; Seyedin, Steven; Marquardt, Michael et al. (2018) Cutaneous malignant melanoma of the oral cavity following skin graft reconstruction: Case report. Head Neck :
D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426
McMaster, Mary L; Berndt, Sonja I; Zhang, Jianqing et al. (2018) Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. Nat Commun 9:4182
Beck, Anna C; Goffredo, Paolo; Hassan, Imran et al. (2018) Risk factors for 30-day readmission after adrenalectomy. Surgery 164:766-773
Gorman, Jacob V; Colgan, John D (2018) Acute stimulation generates Tim-3-expressing T helper type 1 CD4 T cells that persist in vivo and show enhanced effector function. Immunology 154:418-433
El-Galaly, Tarec Christoffer; Cheah, Chan Yoon; Bendtsen, Mette Dahl et al. (2018) Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer 93:57-68
Fama, Angelo; Xiang, Jinhua; Link, Brian K et al. (2018) Human Pegivirus infection and lymphoma risk and prognosis: a North American study. Br J Haematol 182:644-653
Atay, Safinur; Wilkey, Daniel W; Milhem, Mohammed et al. (2018) Insights into the Proteome of Gastrointestinal Stromal Tumors-Derived Exosomes Reveals New Potential Diagnostic Biomarkers. Mol Cell Proteomics 17:495-515

Showing the most recent 10 out of 1080 publications